REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy
Bildiriler > Özet Bildiri · 2014
Yazarlar: Maurice Perol, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay GÖKSEL, Keunchli Park, Ruben Carlo Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey Oriov, Conrad R. Lewanski, Ekaterine Alexandris, Annemaria Zimmerman, Nadia Chouaki, William J. John, Sergey Yurasov, Edward B. Garon
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Amerika Birleşik Devletleri, Uluslararası, Sözlü Sunum, Özet Bildiri, 2014-2014, Wos, cilt 32